Axsome Stock Analysis


USD 48.50  2.42  5.25%   

The new bullish price patterns experienced by current Axsome Thera shareholders could raise concerns from stakeholders as the firm is trading at a share price of 48.50 on 1,110,374 in volume. The company directors and management have been very successful in rebalancing the firm assets at opportune times to take advantage of market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.55. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Axsome Thera partners.
Please continue to Trending Equities.
The Axsome Thera stock analysis report makes it easy to digest most publicly released information about Axsome Thera and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Axsome Stock analysis module also helps to analyze the Axsome Thera price relationship with some important fundamental indicators such as market cap and management efficiency.

Axsome Stock Analysis Notes

About 21.0% of the company shares are held by company insiders. The company has Price/Earnings To Growth (PEG) ratio of 0.19. Axsome Thera recorded a loss per share of 2.77. The entity had not issued any dividends in recent years. Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 116 people. For more info on Axsome Thera please contact Herriot Tabuteau at 212 332 3241 or go to

Axsome Thera Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Axsome Thera's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Axsome Thera or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Axsome Thera has very high historical volatility over the last 90 days
The company reported the previous year's revenue of 8.82 M. Net Loss for the year was (140.78 M) with profit before overhead, payroll, taxes, and interest of 0.
Axsome Thera currently holds about 84.71 M in cash with (113.66 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18.
Roughly 21.0% of the company shares are held by company insiders
Latest headline from AXSM stock gains as sleep disorder therapy increases cognitive function - Seeking Alpha

Axsome Thera Upcoming and Recent Events

Earnings reports are used by Axsome Thera to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Axsome Thera previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report7th of March 2022
Next Financial Report9th of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End7th of March 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Axsome Thera SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Axsome Thera prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Axsome Thera investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Axsome Thera specific information freely available to individual and institutional investors to make a timely investment decision.
8th of September 2022
Financial Statements and Exhibits. Other Events
1st of September 2022
Financial Statements and Exhibits. Other Events
23rd of August 2022
Other Events. Results of Operations and Financial Condition
19th of August 2022
Financial Statements and Exhibits. Other Events
9th of August 2022
Financial Statements and Exhibits. Other Events
21st of July 2022
Financial Statements and Exhibits
28th of June 2022
Financial Statements and Exhibits. Other Events
27th of June 2022
Other Events

Axsome Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Axsome Thera is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Axsome Thera backward and forwards among themselves. Axsome Thera's institutional investor refers to the entity that pools money to purchase Axsome Thera's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Vanguard Group IncCommon Shares2.8 M107.3 M
Blackrock IncCommon Shares2.2 M85.4 M
Rtw Investments LpCommon Shares1.6 M62 M
Pfm Health Sciences LpCommon Shares1.4 M52.1 M
Fairmount Funds Management LlcCommon Shares942.6 K36.1 M
State Street CorpCommon Shares853 K32.7 M
Bellevue Group AgCommon Shares817.1 K31.3 M
Citadel Advisors LlcCall Options607.2 K23.3 M
Ikarian Capital LlcPut Options500 K19.2 M
Note, although Axsome Thera's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Axsome Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.68 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Axsome Thera's market, we take the total number of its shares issued and multiply it by Axsome Thera's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (66.13) % which means that it has lost $66.13 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (253.67) %, meaning that it created substantial loss on money invested by shareholders. Axsome Thera management efficiency ratios could be used to measure how well axsome thera manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 6th of October, Axsome Thera shows the Risk Adjusted Performance of 0.0748, mean deviation of 3.99, and Downside Deviation of 4.32. Axsome Thera technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We are able to interpolate and collect nineteen technical drivers for Axsome Thera, which can be compared to its rivals. Please confirm Axsome Thera standard deviation, maximum drawdown, as well as the relationship between the Maximum Drawdown and expected short fall to decide if Axsome Thera is priced correctly, providing market reflects its regular price of 48.5 per share. Given that Axsome Thera has jensen alpha of 0.3776, we suggest you to validate Axsome Thera's prevailing market performance to make sure the company can sustain itself at a future point.

Axsome Thera Price Movement Analysis

Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Double Exponential Moving Average indicator was developed by Patrick Mulloy. It consists of a single exponential moving average and a double exponential moving average. This indicator is more responsive to Axsome Thera changes than the simple moving average.

Axsome Thera Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Axsome Thera insiders, such as employees or executives, is commonly permitted as long as it does not rely on Axsome Thera's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Axsome Thera insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Axsome Thera Predictive Daily Indicators

Axsome Thera intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Axsome Thera stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Axsome Thera Forecast Models

Axsome Thera time-series forecasting models is one of many Axsome Thera's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Axsome Thera's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Axsome Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Axsome Thera prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Axsome shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Axsome Thera. By using and applying Axsome Stock analysis, traders can create a robust methodology for identifying Axsome entry and exit points for their positions.
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system disorders in the United States. The company was incorporated in 2012 and is based in New York, New York. Axsome Thera operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 116 people.

Current Axsome Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Axsome analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Axsome analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Axsome Thera current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Axsome analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Axsome stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Axsome Thera, talking to its executives and customers, or listening to Axsome conference calls.
Axsome Analyst Advice Details

Axsome Stock Analysis Indicators

Axsome Thera stock analysis indicators help investors evaluate how Axsome Thera stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Axsome Thera shares will generate the highest return on investment. By understating and applying Axsome Thera stock analysis, traders can identify Axsome Thera position entry and exit signals to maximize returns.
Quick Ratio3.45
Fifty Two Week Low20.63
Shares Short Prior Month5.23M
Average Daily Volume Last 10 Day1.23M
Average Daily Volume In Three Month1.52M
Shares Percent Shares Out15.36%
Short Percent Of Float19.34%
Forward Price Earnings-17.64
Float Shares30.91M
Fifty Two Week High71.98
Enterprise Value To Ebitda-10.86
Fifty Day Average51.85
Two Hundred Day Average37.59
Please continue to Trending Equities. You can also try Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.

Complementary Tools for analysis

When running Axsome Thera price analysis, check to measure Axsome Thera's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Axsome Thera is operating at the current time. Most of Axsome Thera's value examination focuses on studying past and present price action to predict the probability of Axsome Thera's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Axsome Thera's price. Additionally, you may evaluate how the addition of Axsome Thera to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
CEO Directory
Screen CEOs from public companies around the world
Is Axsome Thera's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Axsome Thera. If investors know Axsome will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Axsome Thera listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Axsome Thera is measured differently than its book value, which is the value of Axsome that is recorded on the company's balance sheet. Investors also form their own opinion of Axsome Thera's value that differs from its market value or its book value, called intrinsic value, which is Axsome Thera's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Axsome Thera's market value can be influenced by many factors that don't directly affect Axsome Thera's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Axsome Thera's value and its price as these two are different measures arrived at by different means. Investors typically determine Axsome Thera value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Axsome Thera's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.